Targeted Therapy in Hepatocellular Carcinoma

Targeted Therapy in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide, as well as a common cause of cancer-related death. HCC frequently occurs in the setting of a diseased cirrhotic liver and many patients present at an advanced stage of disease. Together with a poor functional status, this often precludes the use of systemic therapy, especially conventional cytotoxic drugs. Moreover, HCC i...

Hepatocellular carcinoma-targeted nanoparticles for cancer therapy

Nanocarriers, such as liposomes, have the potential to increase the payload of chemotherapeutic drugs while decreasing toxicity to non-target tissues; such advantageous properties can be further enhanced through surface conjugation of nanocarriers with targeting moieties. We previously reported that SP94 peptides, identified by phage display, exhibited higher binding affinity to human hepatocel...

Hepatocellular Carcinoma in Sheep

Molecular Targeted Therapy for Growth Factors in Hepatocellular Carcinoma

Treatments for HCC are classified into local and systemic therapies. Various local treatment modalities, such as resection, local ablation, transcatheter arterial chemoembolization (TACE), and liver transplantation, are available at present. The most suitable treatment modality for HCC is selected according to the tumor stage, grade of liver dysfunction, and performance status of the patient [1...

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?